Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA
· Real-Time Price · USD
1.25
0.07 (5.93%)
At close: Sep 16, 2025, 3:59 PM
1.25
0.00%
After-hours: Sep 16, 2025, 04:10 PM EDT
Ernexa Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -3.14M | -8.2M | -5.76M | -26.6M | -5.53M | -6.65M | -6.15M | -5.59M | -4.51M | -5.42M | -4.49M | -7.32M | -3.4M | -9.38M | -8.46M | -86.06M | -10.09M | -17.7M |
Depreciation & Amortization | 55K | 69K | 68K | 451K | 578K | 541K | 481K | 517K | 63K | 62K | 86K | 121K | 152K | 138K | 123.4K | 123.42K | 117.28K | 94.9K |
Stock-Based Compensation | 368K | 502K | 410K | 405K | 423K | 282K | 165K | 174K | 214K | 689K | 397K | 476K | 879K | 1.18M | 1.93M | 1.73M | 1.4M | 169K |
Other Working Capital | -98K | -2K | -602K | -2.53M | 541K | 445K | 3.11M | -2.62M | -1.35M | 286K | -2.38M | 2.37M | 396K | -87K | -330.5K | 308.7K | -1.65M | -789.66K |
Other Non-Cash Items | 690K | 5.34M | 3.16M | 22.74M | 517K | 1.1M | 281K | 52K | 583K | 96K | -1.09M | -845K | -3.83M | 2.22M | 570.04K | 80.61M | -249.91K | 5.2M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | 210K | -20K | -190K | n/a | n/a | n/a | n/a | n/a | 106.00 | -297.28K | 50K | 9.6M |
Change in Working Capital | -506K | 226K | -1.43M | -3.28M | 1.75M | 980K | 355K | -958K | -34K | -1.48M | -343K | 1.45M | 2.21M | 399K | -994.18K | -2.53M | 1.96M | -784.98K |
Operating Cash Flow | -2.53M | -2.06M | -3.54M | -6.29M | -2.26M | -3.75M | -4.66M | -5.83M | -3.87M | -6.05M | -5.43M | -6.12M | -3.99M | -5.43M | -6.83M | -6.42M | -6.8M | -3.43M |
Capital Expenditures | n/a | n/a | n/a | -19K | -249K | -101K | -19K | n/a | n/a | n/a | -21K | -43K | -187K | -46K | -147.14K | -6.86K | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | -4K | n/a | 4K | n/a | n/a | n/a | n/a | 150K | n/a | 100K | n/a | -654 | -22.85M | -466 | 147.73K |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | 4K | n/a | n/a | n/a | n/a | n/a | n/a | 150K | n/a | n/a | n/a | 406.00 | n/a | n/a | 118.59K |
Investing Cash Flow | n/a | n/a | n/a | -19K | -249K | -97K | -19K | n/a | n/a | n/a | 129K | -43K | -87K | -46K | -147.39K | -22.86M | -466 | 266.32K |
Debt Repayment | n/a | 2.25M | n/a | 3.89M | n/a | 1.41M | 7.79M | 8.54M | n/a | n/a | -1K | -1K | n/a | n/a | -410.01K | n/a | n/a | -531.99K |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | 8K | n/a | -8K | n/a | -8K | n/a | -8K | n/a | -8K | n/a | -8K | n/a | -8K | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | n/a | n/a | -14K | -20K | -76K | n/a | -8K | n/a | -111K | 7K | -13K | n/a | -202 | n/a | 10.5M | n/a |
Financial Cash Flow | 4.93M | 2.25M | 1.01M | 3.89M | -22K | 1.39M | 7.7M | 8.54M | 312K | n/a | 7.59M | 6K | -13K | 11.99M | -418.62K | 3.5M | 48.56M | 9.94M |
Net Cash Flow | 2.4M | 189K | -2.54M | 1.68M | -2.53M | -2.46M | 3.02M | 2.71M | -3.56M | -6.05M | 2.29M | -6.15M | -4.09M | 6.51M | -7.4M | -25.78M | 41.75M | 6.78M |
Free Cash Flow | -2.53M | -2.06M | -3.54M | -6.3M | -2.51M | -3.85M | -4.68M | -5.83M | -3.87M | -6.05M | -5.46M | -6.16M | -4.18M | -5.48M | -6.98M | -6.43M | -6.8M | -3.43M |